Last edition
News about "Chris Anzalone"
Arrowhead Pharma Reports Interim Data on Dual RNAi Therapy
Arrowhead Pharmaceuticals has announced interim topline clinical data for the first dual-functional RNAi therapeutic for the treatment of mixed hyperlipidemia.
Chris Anzalone | 17/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members